Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Dr M coming with the heavy artillery next week!
So now we know the WHOLE truth about AF!
I'll go one further... they could go straight to PD P3, since they already know safety and dosage; P2/3 at the very least.
Re: "Shorted at 3.02, pump n dump sucker trap laid out"
You could cover here with only a 10% loss.
I'll give them the benefit of doubt that they could just be that naïve. :)
Up next will be the 36(41)-wk Alz data to provide further focus on monotherapy, dosage mods and more patients on monotherapy...first look at those changes at wk 48(53).
Will you be covering at $3.50 or $4.00?
I totally agree... evidenced by today's PR.
Seriously? You don't see manipulation as a problem? You don't think the price would be much higher if there were no manipulation?
This stock, as well as a lot of other biotechs, will continue to be manipulated until positive news generates large and continuous demand for the stock.
Hedge funds using HFT don't need a lot of shares to manipulate the stock price, when there's little new retail demand.
I suspect that they decided to make changes to patient dosing after 36 weeks; therefore, they will release the data up to that point and collect the next set of data (with the new dosing) at week 48.
If you don't understand that microcap biotechs are heavily manipulated by hedge funds, then you really shouldn't be investing in them.
In hindsight, the fact that AF mentioned the week prior to AAIC, that he had seen the data (which he had NOT), is evidence enough for me that he was planning to release a negative article as cover for the premeditated attack.
Excuse me, but the "market" didn't overreact to the data. As identified and mentioned many times, the SP was taken down by a collusive premeditated attack that was triggered the minute the PR was released. Perhaps many stop-loss orders were triggered along the way to exacerbate the decline.
If the data was truly bad and the trial "garbage", as the cabal's mouthpiece wrote, the SP decline wouldn't have stopped at $2.50.
It would seem to me they inserted wk 48 so that they can get a quicker readout on any recent adaptations they have made to the trial (i.e. dosage changes and/or more monotherapy patients). This might better strengthen the monotherapy case, as well as allow them to fine tune the P3 trial design.
I see this as being good and would expect to see the 36-wk data any day now.
Would love to see a PR for 36 wks that shows the monontherapy results as sustaining or improving and a statement that more patients have been moved to monotherapy.
Seems many here believe that just because "they" manipulated the stock down dramatically, the data must not have been good. That is misguided reasoning (but understandable). Had the manipulators decided to run the price up on the data, then everyone would presume the data was great (sustaining)...also inaccurate. The data is simply inconclusive with the small n; however, it is nonetheless encouraging.
Good thoughts and comments, but I thought the 26-wk (31-wk) study's endpoints were safety and max dosage.
Being an open adaptive trial, one would hope that some of the patients on combo therapy would be taken off donepezil and maintain 2-73 alone.
I've read somewhere that often times the memory is there, but the connection to it has been lost. However, if the brain's neuroplasticity is maintained or restored, then it's possible that new connections can be made to those memories.
Believe me, I'm deeper into this investment than you and I have complete confidence in the company and the science. The cabal will not shake one share loose from my grip. I'm holding for at least another year. Longs will be greatly rewarded and the afflicted treated.
Perhaps the company is concerned about the regulators (SEC). I say, to hell with the regulators; if the SEC isn't going to do anything about the lying hit pieces and incessant attacks on the company, then they should not look negatively on the company promoting its proven successes.
I'm starting to agree... the company needs to improve its public relations efforts. Biogen and Lilly have initiated media blitzes, touting their respective Alz drugs.
The only way Anavex will be able to combat the cabal is by growing awareness... telling its story and the progress of its drugs.
PRs are good, but by themselves have limited effect. We need some visual press and news stories to grow awareness and generate large demand for shares.
To that effort, I emailed the new Media Relations company, stating as such and requesting his comments.
Will let everyone know if I get a reply.
Glad to see they changed the Media Relations company. The previous one did absolutely nothing. Hoping that will change in the coming weeks... I think I'll send him an inquiry.
With options expiring tomorrow, I wouldn't be surprised if the cabal want this to close sub 2.50 for those Sept call options to expire worthless. Perhaps "someone" wrote a bunch of those calls?
I would believe an interview with Dr M, himself, over any articles by Adam Fartstain, Jean Farteneau, Cory Reamaur or Orange Puke Investments. Freakin' cockroaches everywhere!
Go to the link that lists all of the potential and likely positive catalysts...
I pose that those pumping articles were written or paid for by the same cabal that ultimately attacked and took down the stock.
Excellent! Thanks!
nobrainer, thanks for posting that site! I submitted a comment advising them of Anavex (in case they're unfamiliar) and briefly described the science relative to Sig1R and the ER/mitochondria association.
I believe the unwarranted attack is evidence enough that something good is about to happen.
Yes... and that's fine, because on regular terms, dilution would happen very slowly at 50k shares per transaction, every other day.
Read the prospectus that reflects the purchase agreement...
It says that no more than 50k shares can be sold on any given transaction and no more frequent than every other business day...AND AT A MINIMUM PRICE OF $3.
The company has said, it does not intend to issue any of those shares in the near term, as they have enough funds to get them well into 2017.
Absolutely not. Many young biotechs will fail, but my DD tells me that Anavex has the science; the results and related news seem to support that. Why else is the cabal so obsessed with trashing the company and SP...while not being able to refute the science?
Investors only lose if they get scared out and sell at a loss. If they hold, they will very likely be rewarded handsomely within 2 years.
Unfortunately, longs are at the mercy of the cabal until there is positive news announced. Even then, only great news can sustain the SP. Longs just have to wait it out...
You may be right, but I would hope that Dr M has learned his lesson about announcing results at a scheduled conference, as it plays into the cabal's hands. Therefore, I expect the 38-wk data to come via a PR, while the 52-wk data may come at CTAD.
You forgot... Big money is crooked.
When it's being taken down without any negative news, it's called manipulation (same if it were going up). There will be no dilution at these levels IF ANY. It's a big scare tactic by the cabal.
You're spot on, nobrainer. This has been the company's position for some time now; nothing new. This attack was initiated on false assumptions, trying to scare retail into thinking dilution is coming. Even IF AVXL were to raise funds, the purchase agreement specifies only 50k shares per transaction...hardly dilution.
The cabal is hard at work trying to steal our shares before the next positive PR, on 38-wk update, which I'm expecting this month. And potentially others... Rett's and Parkinson's to name a couple. HOLD ONTO YOUR SHARES!